A Novel Radiotherapeutic Platform Targeting Complex Tumors with Precision
At Plus Therapeutics, we’re pioneering a next-generation radiotherapeutic platform designed to deliver targeted cancer treatment with high precision and minimal toxicity.
Our platform is powered by a unique combination of advanced technologies, including:
- Beta- and gamma-energy-emitting Rhenium radionuclides
- Innovative BMEDA chelation techniques for optimized radioisotope loading
- Nanoliposomes for enhanced delivery and tumor penetration
- Biodegradable microspheres that enable controlled and sustained release of radiation
These integrated technologies form the foundation for our lead product candidate, REYOBIQ™ (rhenium Re186 obisbemeda). Engineered to treat aggressive and complex tumors, REYOBIQ™ delivers elevated radiation doses directly to cancer cells while sparing surrounding healthy tissue—a major advancement in precision oncology.
This powerful platform is designed not just for efficacy, but for clinical adaptability, offering a scalable approach to treating cancers with high unmet needs such as glioblastoma (GBM) and leptomeningeal metastases (LM).
🔬 Discover how our radiotherapeutic platform is shaping the future of cancer treatment: https://plustherapeutics.com/our-platform/
#Radiotherapeutics #PrecisionOncology #CancerTreatmentInnovation #Rhenium186 #BMEDAChelation #Nanoliposomes #BiodegradableMicrospheres #REYOBIQ #TargetedRadiation #ClinicalTrials #OncologyResearch #PlusTherapeutics
Recent Comments